Denosumab for Breast Cancer Risk Reduction in Women With an Inherited BRCA1 Mutation (The Breast Cancer Prevention Study)
https://www.facingourrisk.org/research-clinical-trials/study/196/denosumab-for-breast-cancer-risk-reduction-in-women-with-an-inherited-brca1-mutation-the-breast-cancer-prevention-study
Clinicaltrials.gov identifier:
NCT04711109 (https://clinicaltrials.gov/show/NCT04711109)
Prevention study enrolling women ages 25-55 with a BRCA1 mutation
About the Study
NOTE: This study is no longer recruiting patients.
The BRCA-P Study is an international research study for women who are born with a mutation (change) in one of their BRCA1 genes. The main purpose is to find out if the study medication, denosumab, can decrease the risk of developing breast cancer compared to a placebo (inactive substance) in women with a BRCA1 gene mutation.
This Study is Open To:
NOTE: This study is no longer recruiting patients.
This Study is Not Open To:
NOTE: This study is no longer recruiting patients.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.